Health Solutions Company Announces Merger Agreement With Therapeutics Firm

On July 10, 2024, ReShape Lifesciences® (Nasdaq: RSLS), a company in weight loss and metabolic health solutions, announced its entry into a definitive merger agreement with Vyome Therapeutics, Inc., a private clinical-stage company focused on immuno-inflammatory and rare diseases. This merger pinpoints a success for both companies as they aim to leverage their combined strengths to advance medical innovations and expand their reach. Simultaneously, ReShape entered into an asset purchase agreement with Biorad Medisys Pvt. Ltd., which includes the sale of key assets related to ReShape’s weight loss systems. These moves are poised to reshape the landscape of metabolic and immuno-inflammatory health solutions, bridging innovation corridors between India and the United States. $ReShape Lifesciences (RSLS.US)$